|
Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML)
treatment in the late 1990s and substantially changed the therapeutic approach
to the disease, by inducing complete cytogenetic response (CCR) in approximately
60 percent of cases. Nevertheless, some concerns exist about the duration of
response to treatment and the onset of resistance to IM.
|
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
